Abate As Indust

Which are the latest news on Abate As Indust?

Why is Abate As Industries Ltd falling/rising?

As of 05-Sep, Abate As Industries Ltd's stock price is falling, currently at 8.94, reflecting a decrease of 1.54%. The stock has significantly underperformed over the year and is trading below all major moving averages, indicating a bearish trend and declining investor interest.

As of 05-Sep, Abate As Industries Ltd's stock price is falling, currently at 8.94, reflecting a decrease of 0.14 or 1.54%. The stock has underperformed its sector by 2.15% today and has experienced a trend reversal, having fallen after three consecutive days of gains. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Investor participation has also declined, with delivery volume on 03 September dropping by 71.44% compared to the 5-day average. This lack of investor interest contributes to the stock's downward movement. Over the longer term, the stock has significantly underperformed, with a year-to-date decline of 48.91% and a one-year decrease of 54.78%, compared to the Sensex's much smaller declines of 10.21% and 5.21%, respectively. These factors collectively explain the current falling price of Abate As Industries Ltd.

Who are in the management team of Abate As Indust?

The management team of Abate As Indust consists of Kamlesh B Mehta (Executive Director), Visswas B Panse (Independent Non-Executive Director), and Ashok Bhanushali (Non-Executive Director).

The management team of Abate As Indust includes the following individuals:<BR><BR>1. **Kamlesh B Mehta** - Executive Director<BR>2. **Visswas B Panse** - Independent Non-Executive Director<BR>3. **Ashok Bhanushali** - Non-Executive Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Abate As Indust do?

Abate As Industries Ltd is a micro-cap company in the hospital industry, reporting net sales of 23 Cr and a net profit of 2 Cr for June 2026. The company, formerly known as Trijal Industries Limited, has a market cap of INR 142 Cr and key metrics include a P/E ratio of 11.00 and a debt-equity ratio of 0.03.

Overview:<BR>Abate As Industries Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on 26th June 1991 and was originally known as Trijal Industries Limited. It changed its name to Abate As Industries Limited on 21st October 2021. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 23 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 142 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.03<BR>- Return on Equity: 7.09%<BR>- Price to Book: 0.83<BR><BR>Contact Details:<BR>Address: Siddhart Nagar No 5 S V Road, Chawl 19/168 Goregaon West Mumbai Maharashtra : 400062<BR>Email: k4kamleshm@yahoo.com<BR>Website: http://www.abateas.com

Who are the peers of the Abate As Indust?

Abate As Indust's peers include Lotus Eye Hospital, Aashka Hospitals, Fortis Malar, Shanmuga Hospital, Nephro Care, KHFM Hospitality, Vaidya Sane, Maitreya Medica, and Sangani Hospital. Nephro Care shows the best performance with a 1-year return of 0.00%, while Abate As Indust has the lowest at -45.64%.

Peers: The peers of Abate As Indust are Lotus Eye Hospit, Aashka Hospitals, Fortis Malar, Shanmuga Hos., Nephro Care, KHFM Hospitality, Vaidya Sane, Maitreya Medica., and Sangani Hospital.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lotus Eye Hospit, Aashka Hospitals, Fortis Malar, KHFM Hospitality, Vaidya Sane, Maitreya Medica., and Sangani Hospital, while Average management risk is found at Shanmuga Hos. and Nephro Care. Below Average growth is noted for Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, Fortis Malar, KHFM Hospitality, Maitreya Medica., and the rest, while Excellent growth is observed at Nephro Care and Sangani Hospital. Capital Structure ratings show Good at Lotus Eye Hospit and Nephro Care, Average at Aashka Hospitals and Abate As Indust, Below Average at Fortis Malar, KHFM Hospitality, and Maitreya Medica., and Excellent at Shanmuga Hos.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nephro Care at 0.00%, while Abate As Indust has the lowest at -45.64%, indicating a significantly poorer performance compared to its peers. Additionally, Fortis Malar, Shanmuga Hos., and Aashka Hospitals have negative six-month returns.

How big is Abate As Indust?

As of 31st August, Abate As Industries Ltd has a market capitalization of 142.00 Cr and reported net sales of 141.58 Cr and net profit of 12.30 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Abate As Industries Ltd has a market capitalization of 142.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 141.58 Cr, while the sum of Net Profit for the same period is 12.30 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 173.39 Cr and Total Assets totaling 222.72 Cr.

Should I buy, sell or hold Abate As Industries Ltd?

Are Abate As Industries Ltd latest results good or bad?

Abate As Industries Ltd's latest results show a significant year-on-year profit increase of 146.22%, but a concerning 20.50% sequential decline in net sales and low capital efficiency metrics suggest mixed performance. Investors should consider these factors when evaluating the company's future prospects.

Abate As Industries Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹2.93 crore for Q4 FY26, which is a significant improvement of 146.22% year-on-year, indicating a strong operational turnaround from the previous year. Additionally, the profit after tax (PAT) margin improved to 8.63%, up from 8.45% in the same quarter last year, and the operating margin also saw an increase to 9.13% from 5.89%.<BR><BR>However, there are notable concerns. The company experienced a sequential decline in net sales of 20.50%, dropping from ₹42.69 crore in Q3 FY26 to ₹33.94 crore in Q4 FY26. This raises questions about the sustainability of its revenue growth. Furthermore, the return on equity (ROE) remains extremely low at 0.65%, and the return on capital employed (ROCE) is just 0.11%, indicating significant capital efficiency issues.<BR><BR>Overall, while the company has achieved profitability, the substantial decline in sales and weak capital efficiency metrics suggest that the results are not entirely positive. Investors may need to weigh these factors carefully when assessing the company's performance and future prospects.

When is the next results date for Abate As Industries Ltd?

The next results date for Abate As Industries Ltd is 29 May 2026.

The next results date for Abate As Industries Ltd is scheduled for 29 May 2026.

How has been the historical performance of Abate As Indust?

Abate As Indust reported an operating income of 14.09 Cr and a profit after tax of 1.11 Cr for the year ending March 2025, with an EPS of 0.07 and strong profit margins of 5.25% and 7.81%. The company has total liabilities of 205.47 Cr and shareholder's funds of 163.79 Cr, indicating a solid financial position.

Answer:<BR>The historical performance of Abate As Indust shows a total operating income of 14.09 Cr for the year ending March 2025, with a total expenditure of 13.35 Cr, resulting in an operating profit (PBDIT) of 1.71 Cr. After accounting for interest and depreciation, the profit before tax stands at 1.10 Cr, leading to a profit after tax of 1.11 Cr. The earnings per share (EPS) for the same period is reported at 0.07. The company maintains a strong operating profit margin of 5.25% and a profit after tax margin of 7.81%. <BR><BR>Breakdown:<BR>Abate As Indust reported a total operating income of 14.09 Cr, with raw material costs and other operating expenses contributing to a total expenditure of 13.35 Cr. This resulted in an operating profit of 1.71 Cr, which, after deducting interest and depreciation, led to a profit before tax of 1.10 Cr and a profit after tax of 1.11 Cr. The company’s earnings per share is 0.07, reflecting its profitability. The operating profit margin is 5.25%, while the profit after tax margin is notably higher at 7.81%. On the balance sheet, total liabilities amount to 205.47 Cr, with shareholder's funds at 163.79 Cr, indicating a solid financial foundation. The cash flow from financing activities shows a net inflow of 164.00 Cr, contributing to a closing cash equivalent of 1.00 Cr.

Is Abate As Indust overvalued or undervalued?

As of July 17, 2025, Abate As Indust is considered very expensive and overvalued, with a PE ratio of 321.59, significantly higher than its peers, and a recent stock performance of 111.65% compared to the Sensex's 0.83%.

As of 17 July 2025, the valuation grade for Abate As Indust has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 321.59, an EV to EBIT of 362.63, and an ROE of 0.67%. <BR><BR>In comparison to its peers, Abate As Indust's valuation metrics are starkly high; for instance, Elitecon International has a PE ratio of 273.4, while Lloyds Enterprises stands at 178.83. This suggests that Abate As Indust is priced at a premium compared to its competitors. Additionally, the company's recent stock performance has outpaced the Sensex, with a 1-month return of 111.65% compared to the Sensex's 0.83%, reinforcing the notion of an inflated valuation.

Who are the top shareholders of the Abate As Indust?

The top shareholders of Abate As Indust are the Al Salama Eye Research Foundation with 12.75%, followed by Kanta Devi Samdaria at 2.39%, while individual investors hold a combined 58.46%. There are no institutional holdings from mutual funds or foreign investors.

The top shareholders of Abate As Indust include the Al Salama Eye Research Foundation, which holds the largest stake at 12.75%. The highest public shareholder is Kanta Devi Samdaria, with a holding of 2.39%. Additionally, individual investors collectively hold a significant portion of 58.46%. There are no institutional holdings from mutual funds or foreign institutional investors.

What is the technical trend for Abate As Indust?

As of May 19, 2025, Abate As Indust shows a mildly bearish trend due to daily moving averages and weekly RSI indicating bearish momentum, despite mixed signals from other indicators.

As of 19 May 2025, the technical trend for Abate As Indust has changed from does not qualify to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. While the weekly MACD and Bollinger Bands are mildly bullish, the monthly indicators remain bearish, suggesting a lack of strong upward momentum. The Dow Theory indicates no trend on the weekly timeframe, but mildly bullish on the monthly, adding to the mixed signals. Overall, the strength of the bearish stance is supported by the daily moving averages and the weekly RSI.